The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Novartis
Stock and Other Ownership Interests - Novartis; Pfizer
NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) early breast cancer (EBC).
 
Dennis J. Slamon
Leadership - Biomarin
Stock and Other Ownership Interests - Pfizer
Honoraria - Novartis
Consulting or Advisory Role - Lilly; Novartis
Research Funding - Novartis; Pfizer
Travel, Accommodations, Expenses - Biomarin; Novartis; Pfizer
 
Peter A. Fasching
Honoraria - Amgen; AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Hexal; Merck Sharp & Dohme; Myelo Therapeutics GmbH; Novartis; Pfizer; Puma Biotechnology; Roche; Teva
Consulting or Advisory Role - Amgen; AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Hexal; Merck Sharp & Dohme; Myelo Therapeutics GmbH; Novartis; Pfizer; Puma Biotechnology; Roche; Teva
Research Funding - BioNTech (Inst); Novartis (Inst)
 
Ravindranath Patel
Other Relationship - Novartis
 
Sunil Verma
Leadership - Oncology Education
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Lilly; Merck; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; Lilly; Macrogenics; Novartis; Pfizer; Roche/Genentech; Seagen; Spectrum Pharmaceuticals
 
Sara A. Hurvitz
Research Funding - Ambryx (Inst); Amgen (Inst); Bayer (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Cascadian Therapeutics (Inst); Daiichi Sankyo (Inst); Dignitana (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Macrogenics (Inst); Medivation (Inst); Merrimack (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Puma Biotechnology (Inst); sanofi (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Lilly; Novartis; OBI Pharma
 
Stephen K. L. Chia
Honoraria - Genomic Health; Novartis
Consulting or Advisory Role - Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Genentech (Inst); Genomic Health (Inst); Novartis (Inst); Roche (Inst)
 
John Crown
Honoraria - Amgen; Boehringer Ingelheim; Eisai; Genomic Health; Pfizer; Puma Biotechnology; Seagen; Vertex
Speakers' Bureau - Eisai; Pfizer
Research Funding - Boehringer Ingelheim (Inst); Eisai (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bayer; MSD; Pfizer; Roche
 
Miguel Martin
Consulting or Advisory Role - AstraZeneca; Lilly; Novartis; Pfizer; PharmaMar; Roche/Genentech; Taiho Pharmaceutical
Research Funding - Novartis (Inst); Roche (Inst)
 
Carlos H. Barrios
Stock and Other Ownership Interests - Biomarker; MedSIR; Tummi
Honoraria - Boehringer Ingelheim; Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche/Genentech; Sanofi
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Eisai; GlaxoSmithKline; Libbs; MSD Oncology; Novartis; Pfizer; Roche/Genentech; United Medical
Research Funding - AB Science; Abbvie; Abraxis BioScience; Amgen; Asana Biosciences; Astellas Pharma; AstraZeneca; Biomarin; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Celgene; Clinica Atlantis; Covance; Daiichi Sankyo; Daiichi Sankyo; Exelixis; GlaxoSmithKline; GlaxoSmithKline; Halozyme; ImClone Systems; INC Research; inVentiv Health; Janssen; LEO Pharma; Lilly; Medivation; Merck; Merrimack; Millennium; Mylan; Novartis; Pfizer; Roche/Genentech; Sanofi; Taiho Pharmaceutical
Travel, Accommodations, Expenses - AstraZeneca; BMS Brazil; MSD Oncology; Novartis; Pfizer; Roche/Genentech
 
Gonzalo Spera
No Relationships to Disclose
 
Céline Lopez
No Relationships to Disclose
 
Inès Hor
No Relationships to Disclose
 
Diana Pelov
Employment - Novartis
Stock and Other Ownership Interests - Allergan; Novartis
 
Gareth Hughes
Employment - Novartis
 
Moditha Nawinne
No Relationships to Disclose
 
Gabriel N. Hortobagyi
Consulting or Advisory Role - Agendia; Lilly; Merck; Novartis; Peregrine Pharmaceuticals; Roche
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Novartis